Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours

British Journal of Surgery

Volumn 97, Issue 5, 2010, Pages 691-697

  Schiesser, M ^a   Veit Haibach, P ^a   Muller, M K ^a   Weber, M ^a   Bauerfeind, P ^a   Hany, T ^a   Clavien, P A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; DIAGNOSTIC AGENT; DOPA; DRUG DERIVATIVE; INDIUM 111 OCTREOTIDE; INDIUM-111-OCTREOTIDE; OCTREOTIDE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; EVALUATION; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; DIHYDROXYPHENYLALANINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, SPIRAL COMPUTED;

EID: 77951815580     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.6937     Document Type: Article

References (20)

1. Oberg K. Neuroendocrine gastrointestinal tumours. Ann Oncol 1996; 7: 453-463.
2. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program: SEER Stat Database. National Cancer Institute: Bethesda, 2007.
3. Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ami N YAcad Sci 2004; 1014: 13-27. (Pubitemid 38594787)
4. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9: 61-72.
5. Montravers F, Grahek D, Kerrou K, Ruszniewski P, de Beco V, Aide N et al. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? J Nucl Med 2006; 47: 1455-1462. (Pubitemid 47544931)
6. Krausz Y, Keidar Z, Kogan I, Even-Sapir E, Bar-Shalom R, Engel A et al. SPECT/CT hybrid imaging with mIn-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf) 2003; 59: 565-573. (Pubitemid 37357615)
7. Lebtahi R, Cadiot G, Mignon M, Le Guludec D. Somatostatin receptor scintigraphy: a first-line imaging modality for gastroenteropancreatic neuroendocrine tumors. Gastroenterology 1998; 115: 1025-1027. (Pubitemid 28516962)
8. Gibril F, Reynolds JC, DoppmanJL, Chen CC, Venzon DJ, Termanini B et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996; 125: 26-34. (Pubitemid 126505336)
9. 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology 2001; 220: 373-380.
10. Jager PL, Chirakal R, Marriott CJ, Brouwers AH, Koopmans KP, Gulenchyn KY. 6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med 2008; 49: 573-586. (Pubitemid 351520605)
11. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001; 42: 432-445. (Pubitemid 32207394)
12. Heinrich S, Goerres GW, Schafer M, Sagmeister M, Bauerfeind P, Pestalozzi BC et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 2005; 242: 235-243. (Pubitemid 41033440)
13. Naiini C, Fanti S, Rubellob. 18F-DOPAPETand PET/CT.J Nucl Med2007; 48: 1577-1579.
14. Bettini R, Mantovani W, Boninsegna L, Grippa S, Capelli P, Bassi C et al. Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. Dig Liver Dis 2009; 41:49-55.
15. 111In-pentetreotide scintigraphy J Nucl Med 2002; 43: 889-895.
16. Koopmans KP, de Vries EG, Kema IP, Elsinga PH, Neels OC, Sluiter WJ et al. Staging of carcinoid tumours with 18F-DOPAPET: a prospective, diagnostic accuracy study. Lancet Oncol2006; 7: 728-734.
17. 18F] fluoro-L-DOPAPET in the diagnosis of hyperinsulinism of infancy: a retrospective study involving 49 children. Eur J Nucl Med Mol Imaging 2007; 34: 2120-2128.
18. Becherer A, Szabó M, Karanikas G, Wunderbaldinger P, Angelberger P, RadererM et al. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PFT. J Nucl M?¿2004; 45: 1161-1167.
19. Alexander HR, Fraker DL, Norton JA, Bartlett DL, Tio L, Benjamin SB ef al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 1998; 228: 228-238. (Pubitemid 30191719)
20. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C et al. 68 Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48:508-518. (Pubitemid 47571404)